As of 2025-07-06, the EV/EBITDA ratio of Plus Therapeutics Inc (PSTV) is -0.72. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. PSTV's latest enterprise value is 7.17 mil USD. PSTV's TTM EBITDA according to its financial statements is -10.01 mil USD. Dividing these 2 quantities gives us the above PSTV EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.0x - 13.1x | 12.8x |
| Forward P/E multiples | 17.1x - 32.0x | 20.6x |
| Fair Price | (2.81) - (2.11) | (2.74) |
| Upside | -1048.6% - -813.4% | -1023.9% |
| Date | EV/EBITDA |
| 2025-06-24 | -0.09 |
| 2025-06-23 | -0.07 |
| 2025-06-20 | -0.13 |
| 2025-06-18 | -0.18 |
| 2025-06-17 | -0.79 |
| 2025-06-16 | -0.79 |
| 2025-06-13 | -0.82 |
| 2025-06-12 | -1.02 |
| 2025-06-11 | -0.91 |
| 2025-06-10 | -1.02 |
| 2025-06-09 | -1.01 |
| 2025-06-06 | -0.88 |
| 2025-06-05 | -0.85 |
| 2025-06-04 | -1.04 |
| 2025-06-03 | -1.19 |
| 2025-06-02 | -1.12 |
| 2025-05-30 | -0.66 |
| 2025-05-29 | -0.66 |
| 2025-05-28 | -0.58 |
| 2025-05-27 | -0.69 |
| 2025-05-23 | -0.73 |
| 2025-05-22 | -0.81 |
| 2025-05-21 | -0.96 |
| 2025-05-20 | -0.84 |
| 2025-05-19 | -0.94 |
| 2025-05-16 | -1.42 |
| 2025-05-15 | -1.92 |
| 2025-05-14 | -2.06 |
| 2025-05-13 | -3.02 |
| 2025-05-12 | -2.70 |
| 2025-05-09 | -2.80 |
| 2025-05-08 | -2.57 |
| 2025-05-07 | -2.25 |
| 2025-05-06 | -1.88 |
| 2025-05-05 | -2.57 |
| 2025-05-02 | -2.73 |
| 2025-05-01 | -2.75 |
| 2025-04-30 | -3.14 |
| 2025-04-29 | -3.43 |
| 2025-04-28 | -3.86 |
| 2025-04-25 | -3.54 |
| 2025-04-24 | -3.85 |
| 2025-04-23 | -4.66 |
| 2025-04-22 | -3.53 |
| 2025-04-21 | -2.69 |
| 2025-04-17 | -2.79 |
| 2025-04-16 | -2.87 |
| 2025-04-15 | -2.75 |
| 2025-04-14 | -2.68 |
| 2025-04-11 | -3.32 |